Search clinical trials for: NTHi-10-AS01E

Total 3199 results

GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.

Respiratory Disorders

Sweden, United Kingdom
University of Oxford
National Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...

Completed

A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S

Plasmodium Falciparum Malaria

United Kingdom
University of Oxford

Completed

Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults (RTSS)

Malaria Vaccine

Thailand
GlaxoSmithKline

Completed

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Malaria

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

Herpes Zoster

United States, Spain, Czechia
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers

Respiratory Disorders

Belgium
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
GlaxoSmithKline

Completed

Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine

Respiratory Disorders

France, Estonia, Spain, Finland, Italy
GlaxoSmithKline

Completed

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Malaria

Ghana, Kenya
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.

Respiratory Disorders

Belgium
GlaxoSmithKline

Completed

A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine

Respiratory Disorders

Germany, Canada, United Kingdom
GlaxoSmithKline

Completed

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

Respiratory Disorders

France, Germany, Spain, United States, Belgium, Italy, Canada, United Kingdom
GlaxoSmithKline
PATH

Completed

A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

Malaria

United States
National Institute of Allergy and Infectious Diseases...

Completed

Nontypeable H. Influenzae in Healthy Adults

Haemophilus Influenzae (NTHI)

United States
University of Oxford
National Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...

Completed

A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria

Plasmodium Falciparum Malaria

United Kingdom
Sun Pharmaceutical Industries Limited

Completed

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Non-segmental Vitiligo

United States, India
University of Pennsylvania
University of Michigan

Completed

Development of a Tailored HIV Prevention Intervention for Young Men (myDEx)

HIV Infections

United States
Bill & Melinda Gates Medical Research Institute
Bill and Melinda Gates Foundation; Wellcome Trust

Recruiting

Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults

Tuberculosis

Indonesia, Kenya, Malawi, Mozambique, South Africa, Vietnam, Zambia
Bill & Melinda Gates Medical Research Institute
Wellcome Trust

Completed

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV (MESA-TB)

Human Immunodeficiency Virus

South Africa
PATH
GlaxoSmithKline; Kenya Medical Research Institute; US Army Medical Research Directorate-Africa... and other collaborators

Completed

RTS,S/AS01E Hypo-immuno-responsiveness Study

Plasmodium Falciparum

Kenya
Institut Paoli-Calmettes

Completed

Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy (ALLO-WT1)

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

France
Georgetown University

Not yet recruiting

Leveraging Telehealth to Improve Oral Health Among Cancer Survivors

Cancer | Periodontal Diseases | Oral Mucositis
ChairsideSplint.com

Completed

Adjunctive Treatment of Chronic Migraine Using an Oral Dental Device

Chronic Migraine, Headache

United States
GlaxoSmithKline

Completed

A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults

Respiratory Disorders

Belgium
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); The...

Completed

A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults

Malaria

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaborators

Completed

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

Malaria

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

Malaria

United States
KEMRI-Wellcome Trust Collaborative Research Program
GlaxoSmithKline

Unknown

An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial (MAL059)

Malaria

Kenya
GlaxoSmithKline

Completed

A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults

Respiratory Syncytial Virus Infections

Japan
Universitätsklinikum Hamburg-Eppendorf

Recruiting

Nasotracheal Intubation in Critically Ill. (NaTra-P)

Critical Care | Tracheal Intubation Morbidity

Germany
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR); The PATH Malaria...

Completed

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

Plasmodium Falciparum Malaria

United States
University of Oxford

Completed

A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S

Plasmodium Falciparum Malaria

United Kingdom
International AIDS Vaccine Initiative

Completed

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

HIV/AIDS

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.

Plasmodium Falciparum

Kenya
Ministry of Health and Population, Egypt

Completed

Injection of Subcutaneous Glucose 10% in Small Shots is Effective in the Treatment of Diabetic Neuropathic Pain

Painful Diabetic Neuropathy

Egypt
GlaxoSmithKline

Completed

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Influenza, Human

United States, Belgium
Celularity Incorporated

Completed

Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU

Diabetic Foot | Peripheral Arterial Disease

United States
ClinAmygate
Aswan University Hospital

Recruiting

A (5-5-5-8) Technique for Laparoscopic Cholecystectomy

Cholecystolithiasis | Cholecystitis; Gallstone | Cholecystitis, Chronic

Egypt
GlaxoSmithKline

Active, not recruiting

Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Hepatitis B, Chronic

Taiwan, Belgium, Thailand, Germany, Spain, Hong Kong, United Kingdom, France, Poland
GlaxoSmithKline
Walter Reed Army Institute of Research (WRAIR); The PATH Malaria Vaccine Initiative...

Completed

Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Malaria

United States
Jas Chahal

Completed

Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA

Osteoarthritis of Knee

Canada
BNM Clinic and Research

Completed

10 Years Evaluation of Composite Restoration

Dental Restoration, Permanent
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Malaria | Malaria Vaccines

Ghana
Celularity Incorporated

Terminated

Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease

Diabetic Foot | Peripheral Arterial Disease

United States
Aeras
European and Developing Countries Clinical Trials Partnership (EDCTP)

Completed

Study of AERAS-402 in Healthy Infants

Tuberculosis

Kenya, South Africa, Mozambique
Provectus Biopharmaceuticals, Inc.

No longer available

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory | Approved Alternative Therapy

United States, Australia
Provectus Pharmaceuticals

Completed

PV-10 Chemoablation of Recurrent Breast Carcinoma

Breast Cancer

New Zealand
Provectus Pharmaceuticals

Completed

Intralesional PV-10 Chemoablation of Metastatic Melanoma

Melanoma

Australia
Merry, Graham, M.D.

Completed

Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration (TORPA)

Nonexudative Age-related Macular Degeneration

United States, Canada

3

Subscribe